Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196137 | 0.94 | CHRM3 (0.49) | CHRM3CHRM2ADRB2 | |
| SCHEMBL3299868 | 0.94 | CHRM3 (0.49) | CHRM3CHRM2ADRB2 | |
| SCHEMBL268484 | 0.93 | CHRM3 (0.53) | CHRM3CHRM2 | |
| SCHEMBL714031 | 0.93 | CHRM3 (0.53) | CHRM3CHRM2 | |
| SCHEMBL4493974 | 0.90 | CHRM3 (0.38) | CHRM3CHRM2ADRB2 | |
| SCHEMBL5921860 | 0.90 | CHRM3 (0.57) | CHRM3 | |
| SCHEMBL5278240 | 0.90 | CHRM3 (0.52) | CHRM3CHRM2 | |
| SCHEMBL713680 | 0.89 | CHRM3 (0.55) | CHRM3 | |
| SCHEMBL713494 | 0.87 | CHRM3 (0.52) | CHRM3 | |
| SCHEMBL265133 | 0.86 | CHRM3 (0.54) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | claimed |
| US-20130274288-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8487107-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8377966-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120122926-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100125079-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100093753-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7687519-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205777-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 12/4885 |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 15/4885 |
| US-20060205777-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 12/4885 |
| US-20130274288-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 12/4885 |
| US-20100093753-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 12/4885 |
| US-20100125079-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 12/4885 |
| US-20120122926-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.